October 1, 2026
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
Investors
Clinical Development Pipeline
Learn More
Quarterly Results
View Results
2025 Year in Review
View This Report
Key Ratios
Key Financial Ratios
Sustainability Report
Learn More
Latest Sustainability Developments
View Stories

Investor Email Alerts
Sign up to receive email alerts for various types of investor content.